Abstract
Infliximab as First‐Line Therapy in Severe Pediatric Crohn Disease
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Paper version not known
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callMore From: Journal of Pediatric Gastroenterology and Nutrition
Paper Title
Journal
Date
